882977-63-1

Basic information

• Product Name: 1-(5,6-Dichloro-1H-benzo[d]iMidazol-2-yl)ethanone
• Synonyms: 1-(5,6-Dichloro-1H-benzo[d]iMidazol-2-yl)ethanone;1-(5,6-Dichloro-1H-benzoimidazol-2-yl)-ethanone
• CAS NO: 882977-63-1
• Molecular Formula: C₉H₆Cl₂N₂O
• Molecular Weight: 229.06274
• Mol File: 882977-63-1.mol

Chemical Properties

• Boiling Point: 415.3±48.0 °C(Predicted)
• Appearance: /
• Density: 1.521±0.06 g/cm3(Predicted)
• PKA: 7.52±0.10(Predicted)
• CAS DataBase Reference: 1-(5,6-Dichloro-1H-benzo[d]iMidazol-2-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5,6-Dichloro-1H-benzo[d]iMidazol-2-yl)ethanone(882977-63-1)
• EPA Substance Registry System: 1-(5,6-Dichloro-1H-benzo[d]iMidazol-2-yl)ethanone(882977-63-1)

Safety Data

• Hazardous Substances Data: 882977-63-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(5,6-Dichloro-1H-benzo[d]iMidazol-2-yl)ethanone is used as an important intermediate in the production of various pharmaceuticals. Its unique structure allows it to be a key component in the synthesis of drugs with diverse therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 1-(5,6-Dichloro-1H-benzo[d]iMidazol-2-yl)ethanone is utilized as a reagent in the synthesis of agrochemicals. Its properties make it suitable for the development of compounds that can be used in crop protection and other agricultural applications.
Used in Antimicrobial Applications:
1-(5,6-Dichloro-1H-benzo[d]iMidazol-2-yl)ethanone has been studied for its antimicrobial properties, making it a potential candidate for use in the development of new antimicrobial agents to combat resistant bacteria and other pathogens.
Used in Antiparasitic Applications:
1-(5,6-Dichloro-1H-benzo[d]iMidazol-2-yl)ethanone has also shown antiparasitic activity, indicating its potential use in the development of treatments for various parasitic infections.
Used in Anticancer Applications:
1-(5,6-Dichloro-1H-benzo[d]iMidazol-2-yl)ethanone has been investigated for its potential anticancer properties, suggesting that it could be used in the development of new cancer therapies.
Used in Neurological Disorder Treatment:
Due to its potential neuroprotective effects, 1-(5,6-Dichloro-1H-benzo[d]iMidazol-2-yl)ethanone has been studied for its use in the treatment of certain neurological disorders, offering hope for new therapeutic approaches.
Overall, 1-(5,6-Dichloro-1H-benzo[d]iMidazol-2-yl)ethanone is a versatile chemical compound with a wide range of potential applications across different industries, and its continued study may lead to new and innovative uses in the future.

Upstream product

• 6641-64-1 4,5-dichloro-2-nitroaniline 
• 5348-42-5 4,5-Dichloro-1,2-phenylenediamine 
• 929079-82-3 1-(5,6-dichlorobenzoimidazol-2-yl)ethanol 

Relevant articles and documents

Anion-Dependent Binding-Mode Changes in meso-(5,6-Dichlorobenzimidazole) Picket Calix[4]pyrrole

A deep-cavity calix[4]pyrrole anion receptor bearing 5,6-dichlorobenzimidazole subunits at diametrically opposed meso positions was synthesized and its anion-binding properties were investigated. The synthesized receptor showed higher affinity for fluoride anions than for chloride anions with a high discrimination factor. Significant differences in the solid-state geometries between the fluoride and chloride complexes were observed.

Novel cathepsin K inhibitors block osteoclasts in vitro and increase spinal bone density in zebrafish

Cathepsin K (Cat K) is a predominant cysteine protease and highly potent collagenase expressed in osteoclasts. Cat K inhibitors are anti-resorptive agents to treat osteoporosis. A novel scaffold of cathepsin K inhibitors, exemplified by lead compound 1x, was used as the template for designing and synthesizing a total of 61 derivatives that have not been reported before. An exploratory structure-activity relationship analysis identified the potent Cat K inhibitor A22, which displayed an IC50 value of 0.44 μM against Cat K. A22 was very specific for Cat K and caused a significantly higher in vitro inhibition of the enzyme as compared to that of lead compound 1x. A surface plasmon resonance analysis confirmed in vitro binding of A22 to Cat K. Molecular docking studies indicated several favourable interaction sites for A22 within the active pocket of Cat K. Furthermore, A22 also blocked active osteoclasts in vitro and increased spinal bone density in zebrafish, in which it showed an activity that was higher than that of the marketed therapeutic bone metabolizer etidronate disodium. A22 represents a very promising lead compound for the development of novel antiresorptive agents functioning as orthosteric inhibitors of Cat K.

Synthesis and SAR of potent and selective androgen receptor antagonists: 5,6-Dichloro-benzimidazole derivatives

The synthesis and in vivo SAR of 5,6-dichloro-benzimidazole derivatives as novel selective androgen receptor antagonists are described. During screening of 2-alkyl benzimidazoles, it was found that a trifluoromethyl group greatly enhances antagonist activity in the prostate. Benzimidazole 1 is a potent AR antagonist in the rat prostate (ID50 = 0.15 mg/day).